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Abstract
BACKGROUND AND OBJECTIVE—Surveillance for laboratory-confirmed influenza-
associated pediatric deaths since 2004 has shown that most deaths occur in unvaccinated children. 
We assessed whether influenza vaccination reduced the risk of influenza-associated death in 
children and adolescents.
METHODS—We conducted a case-cohort analysis comparing vaccination uptake among 
laboratory-confirmed influenza-associated pediatric deaths with estimated vaccination coverage 
among pediatric cohorts in the United States. Case vaccination and high-risk status were 
determined by case investigation. Influenza vaccination coverage estimates were obtained from 
national survey data or a national insurance claims database. We estimated odds ratios (OR) from 
logistic regression comparing odds of vaccination among cases with odds of vaccination in 
comparison cohorts. We used Bayesian methods to compute 95% credible intervals for vaccine 
effectiveness (VE), calculated as (1 – OR) × 100.
RESULTS—From August 2010 through July 2014, 358 laboratory-confirmed influenza-
associated pediatric deaths were reported among children aged 6 months through 17 years. 
Vaccination status was determined for 291 deaths; 75 (26%) received vaccine before illness onset. 
Average vaccination coverage in survey cohorts was 48%. Overall VE against death was 65% 
(95% credible interval: 54–73). Among 153 deaths in children with underlying high-risk medical 
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conditions, 47 (31%) were vaccinated. VE among children with high-risk conditions was 51% 
(95% credible interval: 31-67), versus 65% (95% credible interval: 47-78) among children without 
high-risk conditions.
CONCLUSIONS—Influenza vaccination was associated with reduced risk of laboratory-
confirmed influenza-associated pediatric death. Increasing influenza vaccination could prevent 
influenza-associated deaths among children and adolescents.
INTRODUCTION
In the United States, annual influenza vaccination of children is recommended to reduce 
adverse health impacts of influenza and prevent severe complications.1 While uncommon, 
influenza-associated deaths among children occur annually with varying incidence 
depending upon the severity of the influenza season.2, 3 From 1976 to 2007, influenza was 
estimated to account for more than 100 deaths annually among children and adolescents.4, 5 
Since 2004, when influenza-associated deaths among children aged <18 years became 
nationally notifiable,6 reported numbers of deaths have ranged from 37 in the 2011-2012 
season to 282 during the 2009 pandemic.2 Surveillance for pediatric deaths has contributed 
to identification of groups at high risk of influenza-related mortality such as children with 
neurologic conditions,7 as well as documenting fatal illness among children with and 
without underlying high-risk medical conditions.3 Previous reports have indicated low rates 
of influenza vaccination among pediatric deaths despite high prevalence of underlying 
medical conditions that increase risk for influenza complications.3, 8 In this analysis, we 
used a case-cohort approach comparing influenza vaccination rates among influenza-
associated pediatric deaths with vaccination coverage estimates for cohorts of U.S. children 
to estimate effectiveness of influenza vaccination against laboratory-confirmed influenza 
associated death.
METHODS
Influenza-Associated Pediatric Deaths
To estimate influenza vaccine effectiveness against death, we used a case-cohort design (or 
screening method).9, 10 Cases were deaths in U.S. residents aged <18 years with laboratory-
confirmed influenza virus infection that were reported to the Influenza-Associated Pediatric 
Mortality Surveillance System.3 Data obtained from standardized case report forms included 
demographic characteristics, state of residence, results of laboratory testing, underlying 
high-risk medical conditions and influenza vaccination status. Confirmation of influenza 
virus infection included clinical diagnostic testing during illness or post-mortem 
examination using antigen detection, viral culture or nucleic acid amplification. We included 
children at least 6 months old on November 1 of the influenza season during which death 
occurred who were eligible to receive at least one dose of seasonal influenza vaccine and 
had complete medical history; 10 deaths among children who turned 6 months old after 
November 1 were excluded. For cases without illness onset date, we estimated onset as four 
days before death based on the mean duration of illness among cases with known onset date. 
We excluded seven children who received their first dose of current season vaccine <14 days 
before illness onset because vaccine-induced protection may be incomplete.11
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Health department personnel determined vaccination status based upon review of available 
information from the child’s medical records, health care provider, state or county 
immunization information systems, parental report or coroner’s report. Children were 
considered vaccinated (either fully or partially) if records indicated receipt of 1 or more 
doses of current season influenza vaccine at least 14 days before onset of illness. Partial 
vaccination was defined as receipt of one dose when health department personnel 
determined that two doses were indicated. Vaccination status was listed as unknown if 
surveillance personnel could not determine from available records if the child had received 
influenza vaccine. If immunization records indicated vaccination for prior seasons but no 
current season vaccination, children were assumed to be unvaccinated. A sensitivity analysis 
explored effects of assuming that children with unknown vaccination status were 
unvaccinated. Presence of underlying medical conditions was recorded on case report forms 
according to high-risk conditions for influenza-related complications identified by the 
Advisory Committee on Immunization Practices:12 asthma, chronic lung disease, 
neurologic/neurodevelopmental disorders, heart disease (including congenital heart disease), 
blood disorders, endocrine disorders, metabolic disorders, kidney disorders, liver disorders, 
immunosuppression and pregnancy. For consistency with vaccination coverage estimates, 
age groups were defined based on child’s age on November 1 for influenza season of fatal 
illness.
Influenza Vaccination Coverage in Cohorts
We used three sources of influenza vaccination coverage among comparison cohorts of U.S. 
children and adolescents: National Immunization Survey-Flu (NIS-Flu),13 National Health 
Interview Survey (NHIS)14 and the MarketScan Commercial Claims and Encounters 
database (Truven Health Analytics, Ann Arbor, Michigan). NIS-Flu is a national telephone 
survey of households with children aged 6 months through 17 years that produces national 
and state-level estimates (and for some cities, including Chicago and New York City) of 
influenza vaccine coverage for children. NHIS is an in-person household survey that 
provides nationally representative estimates of influenza vaccination for children aged 6 
months through 17 years with and without specified high-risk medical conditions (cystic 
fibrosis, sickle cell anemia, diabetes, congenital heart disease or other heart condition, 
cerebral palsy, muscular dystrophy, or seizures; or an asthma episode in the past 12 
months.)15 In NIS-Flu and NHIS, seasonal influenza vaccination coverage is estimated from 
parental report of child’s receipt of ≥1 dose of seasonal influenza vaccine. Data from NIS-
Flu and NHIS are weighted by age, sex, race/ethnicity and geographic area to represent the 
U.S. population. Monthly coverage estimates and standard errors for vaccination received 
during July or August (depending upon survey and season) through May were calculated by 
Kaplan-Meier survival analysis of data from interviews conducted from August, September 
or October through June.16 Age group was based upon the child’s age on November 1 of 
each influenza season.
In the MarketScan Commercial Claims and Encounters database, coverage estimates were 
based on commercial insurance claims for influenza vaccination; children with no 
vaccination claim were assumed unvaccinated. We analyzed data from July 2010 through 
June 2014 among children continuously enrolled in a health plan from January preceding 
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each influenza season. We determined underlying high-risk medical conditions based on 
International Classification of Disease 9th revision codes associated with hospitalizations 
and outpatient visits during a 12-month period.17 We calculated cumulative vaccination 
coverage from August through May each season among children aged <18 years with and 
without underlying high-risk medical conditions. Age categories were based on child’s age 
at vaccination or at the beginning of each calendar year; children in the youngest age 
category (0-4 years) were at least 10 months old on November 1. For MarketScan 
comparison cohorts, state-level coverage estimates were used for children without high-risk 
conditions while national coverage estimates were used for children in high-risk groups due 
to smaller sample sizes.
Analysis
The case-cohort method9, 10 produces an odds ratio (OR), which estimates the relative risk 
for influenza-associated death among vaccinated versus unvaccinated children. Influenza 
vaccine effectiveness (VE) was estimated as (1 – OR). ORs were obtained from logistic 
regression models where vaccination status of the case was the dependent variable and the 
log odds of vaccination (proportion vaccinated/1 – proportion vaccinated) in the comparison 
cohort from NIS-Flu, NHIS, or MarketScan data was entered as an offset. With this offset in 
the model, the intercept provides an estimate of the log(OR). Cases and corresponding 
coverage estimates were stratified by influenza season, age, and state of residence (for NIS-
Flu and MarketScan) or high risk condition (for NHIS and MarketScan) for the month 
ending at least two weeks before case illness onset. For average coverage estimates by age 
group, season or influenza virus type, we derived confidence limits by averaging the 
variance of independent, normally-distributed coverage estimates. To incorporate uncertainty 
in coverage estimates from survey data, 10,000 estimates were sampled from normally 
distributed vaccination coverage estimates for NIS-Flu and NHIS comparison cohorts to 
calculate 95% credible intervals for VE estimates. Because MarketScan estimates were 
derived from all observations without sampling, confidence limits for VE estimates using 
MarketScan data were estimated from logistic regression assuming fixed coverage estimates. 
We assumed that cases did not contribute uncertainty to VE estimates. Sensitivity analyses 
were conducted assuming 1) cases with unknown vaccination status were unvaccinated and 
2) coverage estimates based on parental report over-estimated coverage by 10% or 
20%.18, 19 χ2 tests were used to evaluate proportions and two-sided P values < .05 were 
considered significant. Analyses were conducted in SAS, version 9.4 (SAS Institute, Cary, 
NC) and R (version 3.1.1; R Core Team, Vienna, Austria).
RESULTS
This analysis included 358 influenza-associated pediatric deaths that occurred during four 
influenza seasons from July 1, 2010 through June 30, 2014 among children aged 6 months 
through 17 years. Deaths were reported from 43 states, New York City, Chicago and 
Washington, D.C. Vaccination status was unknown for 67 (19%) children who died. Of 291 
deaths in children with known vaccination status, 75 (26%) children had received seasonal 
influenza vaccination ≥14 days before illness onset and were considered vaccinated. Vaccine 
type was recorded for 62 cases: 12 (19%) received live-attenuated influenza vaccine and 50 
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(81%) received inactivated influenza vaccines. Vaccinated proportions were similar for 
males and females, and did not differ significantly by age category (Table 1). Black, non-
Hispanic children had significantly lower vaccination rates compared with White, non-
Hispanic children (P < .05). Among 31 deaths in vaccinated children aged 6 months through 
4 years, 16 (52%) were partially vaccinated.
A total of 153 (53%) of 291 pediatric deaths with known vaccination status occurred among 
children with one or more ACIP underlying high-risk medical conditions. The prevalence of 
high risk conditions among pediatric deaths increased from 41% among those aged 6 months 
– 4 years to 57% and 62% among 5-12 and 13-17 year olds, respectively. While the 
proportion of children vaccinated increased from 20% among those without high-risk 
conditions to 31% among those with ≥1 high-risk condition and 37% among those with ≥2 
high-risk conditions, fewer than 50% of children in all individual high-risk categories were 
vaccinated (Table 1).
Average influenza vaccination coverage among comparison cohorts in the month preceding 
case illness onset was higher than vaccinated proportions among pediatric deaths for most 
months (Figure). Among deaths in children with known vaccination status, children who 
died had lower vaccination uptake for all age categories, seasons, and infecting influenza 
virus types than the NIS-Flu cohort (Table 2). Overall, average vaccination coverage was 
48% among NIS-Flu comparison cohorts. Estimated VE against pediatric death was 65% 
(95% credible interval [CI]: 54-74). Estimated VE ranged from 40% among 13-17 year olds 
to 76% among 5-12 year olds. By season, VE ranged from 54% in 2010-2011 to 80% (with 
overlapping confidence intervals) in the relatively mild 2011-2012 season with the lowest 
number of pediatric deaths. By virus type, VE point estimates were similar against death 
associated with influenza A virus (66%) and influenza B virus (62%).
Vaccination uptake among pediatric deaths was also lower than average coverage in the 
NHIS comparison cohorts with or without high-risk conditions (Table 3). Estimated VE was 
51% (95% CI: 31-67) among children with high-risk medical conditions and 65% (95% CI: 
47-78) among those without high-risk conditions, similar to VE estimated using NIS-Flu. 
VE point estimates were lower among children with high-risk conditions compared to those 
without high-risk conditions in most analyses, but credible intervals widely overlapped. 
Among children with high-risk conditions, VE estimates were statistically significant (95% 
credible intervals not overlapping zero) only for children aged 5-12 years. Estimated VE was 
statistically significant for three of four seasons among both children with and without high-
risk conditions, for influenza A virus infections among both groups of children and for 
influenza B virus infections among children without high-risk conditions.
Table 4 compares the prevalence of high-risk conditions and uptake of influenza vaccination 
among influenza-associated pediatric deaths and children in the MarketScan database 
(including an average of more than six million individuals aged <18 years during the four 
influenza seasons). Vaccination coverage in MarketScan among children aged <18 years by 
high risk group ranged from 27% among those with no high-risk condition to 45% among 
children with two or more high-risk conditions (Table 4). Prevalence of high-risk conditions 
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was higher among pediatric deaths compared to the MarketScan cohort, and vaccination 
rates were lower among pediatric deaths for most high-risk groups.
In sensitivity analysis treating deaths with unknown vaccination status as unvaccinated, 
overall VE increased to 74% for the NIS-Flu cohort, 73% for the NHIS cohort without high-
risk conditions and 50% for the MarketScan cohort without high-risk conditions (Table 5). 
Alternatively, assuming 10% over-estimation of vaccination by parental report in the survey 
data led to estimates of 56% with NIS-Flu and 58% with the NHIS no high-risk cohort. 
MarketScan estimates treating deaths with unknown vaccination status as unvaccinated were 
similar to NHIS estimates assuming 20% over-estimation of coverage by parental report. VE 
estimates among children with high-risk conditions were lower than among those without 
high-risk conditions for MarketScan as well as NHIS cohorts. Estimated VE among children 
with high-risk conditions remained statistically significant after decreasing NHIS coverage 
estimates by 10% while that among children without high-risk conditions remained 
significant when NHIS estimates were decreased by 20%.
DISCUSSION
We utilized national surveillance data on laboratory-confirmed influenza deaths and three 
comparison cohorts over four influenza seasons to estimate the effectiveness of influenza 
vaccination to prevent influenza-associated pediatric deaths. Best estimates using NHIS 
survey data suggested that vaccination reduced the risk of influenza-associated death by half 
among children with high-risk conditions and by nearly two-thirds among children without 
high-risk conditions. Despite high prevalence (53%) of underlying conditions that increase 
risk of severe influenza-related complications, only one in four children who died with 
laboratory-confirmed influenza had been vaccinated. These results reinforce the need to 
increase influenza vaccination coverage, especially among children at increased risk of 
influenza-related complications and death.
To our knowledge, this is the first study to use laboratory-confirmed outcomes to investigate 
influenza vaccine effectiveness against influenza-associated deaths. Observational studies 
that have used nonspecific outcomes, such as all-cause mortality, have frequently over-
estimated effects of influenza vaccination on mortality in the elderly.20–22 Estimates of VE 
against death from this analysis were similar to VE against medically attended influenza 
among pediatric patients for the same seasons. For 2011-2012 through 2013-2014, estimated 
VE against medically attended influenza ranged from 45% to 57% among young children 
(ages 6 months through 8 years), and from 39% to 58% among older children aged 9 to 17 
years.23–26 In addition, estimated VE against severe life-threatening influenza among 
children admitted to pediatric intensive care units during the 2010-2011 and 2011-2012 
seasons was 74%.27 VE against medically attended influenza has been used in models to 
estimate deaths averted by influenza vaccination.28 Results of this analysis support the use 
of VE against medically attended influenza to estimate deaths averted by influenza 
vaccination.
Case-cohort analyses have previously been used to estimate influenza VE against laboratory-
confirmed influenza,29 effectiveness of seasonal influenza vaccine against influenza 
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A(H1N1)pdm09-associated illness,30 and risk factors for hospitalization and death due to 
influenza A(H1N1)pdm09 infection.31 In the main analyses, VE estimates were based on 
comparisons to NHIS and NIS-Flu, the two surveys used to measure influenza vaccine 
coverage among U.S. children. NHIS includes coverage estimates among children with 
high-risk conditions and NIS-Flu, with its larger sample size, provides state-level 
vaccination coverage. NHIS has been considered the most representative source for 
influenza vaccination coverage estimates among children15 and is used as the data source to 
track progress towards Healthy People 2020 goals.32 VE estimates based on NIS-Flu were 
similar to those based on the NHIS cohort without high-risk conditions.
This study highlights the importance of annual influenza vaccination for children, especially 
those with underlying high-risk medical conditions. Previous reports have highlighted the 
high prevalence of underlying high-risk conditions among children who die from influenza-
related complications, including neurologic disorders and conditions associated with 
underlying chromosomal abnormalities and genetic syndromes.3, 7, 33 While children with 
high-risk conditions in both the NHIS and MarketScan data were more likely than children 
without high-risk conditions to be vaccinated, vaccination coverage among high-risk 
children remained below the Healthy People 2020 target of 70% during these seasons.32 
Because of increased risk of severe complications and influenza-associated death among 
children with underlying conditions, vaccination is especially important for these children. 
Previous reports have also highlighted the occurrence of influenza-associated death in 
previously healthy children with no reported high risk conditions.3, 34 The present study 
indicates that while VE estimates tended to be higher among children without underlying 
high risk conditions, significant protection was demonstrated for both groups of children for 
most seasons.
This analysis is subject to several limitations. Coverage estimates from NIS-Flu and NHIS 
rely on accuracy of parental report of influenza vaccination, which has been found to over-
estimate provider report of coverage.18 Over-reporting may be more common for 
adolescents and children with high-risk conditions.19 The MarketScan database only 
included privately insured children and vaccination rates based on insurance claims of 
influenza vaccination were lower than those based on reported vaccination for the NHIS 
cohort. However, MarketScan estimates were also lower than observed vaccination rates 
(53% to 56% among children aged 6 months through 8 years and 37% to 43% among those 
aged 9-17 years) among influenza-negative children enrolled in the outpatient Influenza 
Vaccine Effectiveness network from 2011-2012 to 2013-2014.23–25 Sensitivity analysis 
suggested that vaccination still provided protection against death assuming 10% to 20% 
over-reporting in NHIS, which resulted in similar estimates to comparisons with MarketScan 
cohorts. An alternative source of comparison coverage would be immunization information 
systems, but reporting of influenza vaccination for children is not mandatory in all states.35 
The majority of pediatric deaths with unknown vaccination status had no documentation of 
influenza vaccination in immunization information systems and were likely unvaccinated; 
sensitivity analyses treating these deaths as unvaccinated resulted in higher VE estimates. 
Vaccination coverage in the comparison cohorts was likely intermediate between estimates 
based on parental report and those based on insurance claims.18 Finally, our analysis 
excluded deaths among infants who became eligible for vaccination after November 1 of 
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each season and included partially vaccinated children; partial vaccination provided no 
protection against severe influenza in a study conducted among children with influenza 
admitted to pediatric intensive care units.27
Results of this study suggest that vaccination reduced the risk of influenza-associated death 
among children and adolescents and add to the evidence of benefits of influenza vaccination 
for children. Annual vaccination is an important strategy to prevent influenza and influenza-
associated complications and deaths. These results support current recommendations for 
annual influenza vaccination for all children ≥6 months of age.
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Table of Contents Summary
This study estimates influenza vaccine effectiveness against deaths among children with 
and without underlying high-risk medical conditions using a case-cohort approach.
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What’s Known on This Subject
Annual influenza vaccination is recommended beginning at 6 months of age to prevent 
influenza and its complications. Most influenza-associated pediatric deaths occur in 
unvaccinated children. Evidence for effectiveness of vaccination in preventing influenza-
associated deaths is needed.
What This Study Adds
This study estimated influenza vaccine effectiveness of 65% (95% confidence interval: 
54-73) to prevent laboratory-confirmed influenza-associated death among children. 
Vaccine effectiveness was lower for children with underlying medical conditions but 
protection remained significant. Sensitivity analyses support the robustness of these 
findings.
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Figure. Comparison of Vaccination Coverage Among Influenza-Associated Pediatric Deaths and 
Comparison Cohorts During Four Influenza Seasons, According to Month of Death
Note: Number of deaths shown in parentheses. Coverage estimates for comparison cohorts 
correspond to month preceding case illness onset.
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Table 1
Characteristics of Influenza-Associated Pediatric Deaths With Known Vaccination Status, United States, 
2010-11 to 2013-14 Influenza Seasons (N=291)a
Total Vaccinatedb
Characteristic No. % No. % vaccinated
Overall 291 75 26
Gender
 Female 135 46 30 22
 Male 156 54 45 29
Age
 6 months to 4 years 93 32 31 33
 5 to 12 years 128 44 26 20
 13 to 17 years 70 24 18 26
Race/ethnicity
 White, non-Hispanic 154 53 42 27
 Hispanic or Latino 57 20 12 21
 Black, non-Hispanic 39 13 3 8
 Asian/Pacific Islander 12 4 8 67
 American Indian/Alaskan Native 7 2 2 29
 Identified by ≥2 races 1 <1 1 100
 Unknown 21 7 7 33
High-risk medical conditions c
 No high-risk medical conditions 135 47 27 20
 One or more high-risk medical conditiond 153 53 47 31
  Chronic pulmonary disease (including asthma) 72 25 25 35
  Metabolic disorders (including diabetes) 18 6 8 44
  Neurologic and neuromuscular disorders 75 26 25 33
  Renal disease 3 1 0 0
  Cardiac or congenital heart disease 30 10 7 23
  Immunosuppressive condition 15 5 7 47
  Pregnancy 2 1 0 0
 Two or more high-risk medical conditionsd 46 16 17 37
 Other high-risk conditions e 37 13 13 35
Location of death f
 In hospital 189 66 54 29
 Emergency department 54 19 17 31
 Outside hospital 45 15 3 7
Influenza virus type/subtype
 Influenza A 173 59 44 25
  A(H1N1)pdm09 87 30 24 28
  A(H3N2) 68 23 15 22
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Total Vaccinatedb
Characteristic No. % No. % vaccinated
  A, subtype not distinguished
 Influenza B 113 39 31 27
 Co-infection (types A and B) 5 2 0 0
a
Excludes children with unknown vaccination status.
b
Receipt of at least one dose of influenza vaccine ≥14 days before onset of illness for season in which death occurred.
cCase investigation form indicates presence of high-risk condition, as defined by Advisory Committee on Immunization Practices guidance for 
conditions that increase risk for complications of influenza. High risk status was not reported for 3 deaths.
d
More than one medical condition could be reported for each pediatric death.
e
Includes chromosomal abnormalities, genetic syndromes and mitochondrial disorders.
f
Location of death was missing for 3 deaths.
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31
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ig
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N
IS
-F
lu
, N
at
io
na
l I
m
m
un
iz
at
io
n 
Su
rv
ey
-F
lu
; N
H
IS
, N
at
io
na
l H
ea
lth
 In
te
rv
ie
w
 S
ur
ve
y;
 L
CL
, l
ow
er
 9
5%
 co
nf
id
en
ce
 li
m
it;
 U
CL
, u
pp
er
 9
5%
 co
nf
id
en
ce
 li
m
it;
 C
I, 
cr
ed
ib
le
 in
te
rv
al
; V
E,
 v
ac
ci
ne
 e
ffe
ct
iv
en
es
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a A
v
er
ag
e 
co
v
er
ag
e 
es
tim
at
e 
fo
r N
IS
-F
lu
 c
oh
or
t p
ai
re
d 
w
ith
 p
ed
ia
tri
c 
de
at
h 
by
 se
as
on
, a
ge
 g
ro
up
, s
ta
te
 o
f r
es
id
en
ce
 a
nd
 m
on
th
 p
re
ce
di
ng
 il
ln
es
s o
ns
et
.
b S
ur
ve
y 
co
v
er
ag
e 
es
tim
at
es
 fo
r e
ac
h 
co
m
pa
ris
on
 c
oh
or
t w
er
e 
in
cr
ea
se
d 
by
 1
0%
 o
r r
ed
uc
ed
 b
y 
10
%
 o
r 2
0%
c A
v
er
ag
e 
na
tio
na
l c
ov
er
ag
e 
es
tim
at
e 
fo
r N
H
IS
 a
nd
 M
ar
ke
tS
ca
n 
co
m
pa
ris
on
 c
oh
or
ts 
pa
ire
d 
w
ith
 p
ed
ia
tri
c 
de
at
h 
by
 se
as
on
, a
ge
 g
ro
up
, h
ig
h 
ris
k 
sta
tu
s, 
an
d 
m
on
th
 p
re
ce
di
ng
 il
ln
es
s o
ns
et
.
d 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s f
or
 V
E 
fro
m
 lo
gi
sti
c 
re
gr
es
sio
n 
w
ith
 o
dd
s o
f v
ac
ci
na
tio
n 
in
 M
ar
ke
tS
ca
n 
co
m
pa
ris
on
 c
oh
or
t e
nt
er
ed
 a
s a
n 
of
fs
et
.
e F
o
r 
ch
ild
re
n 
w
ith
ou
t h
ig
h 
ris
k 
co
nd
iti
on
s, 
sta
te
-s
pe
ci
fic
 c
ov
er
ag
e 
es
tim
at
es
 w
er
e 
us
ed
 fo
r M
ar
ke
tS
ca
n 
co
m
pa
ris
on
 c
oh
or
ts 
pa
ire
d 
w
ith
 p
ed
ia
tri
c 
de
at
h 
by
 se
as
on
, a
ge
 g
ro
up
 a
nd
 m
on
th
 p
re
ce
di
ng
 il
ln
es
s 
o
n
se
t.
Pediatrics. Author manuscript; available in PMC 2018 May 01.
